The global docetaxel market size was valued at USD 1.10 billion in 2024, and it is estimated to reach from USD 1.22 billion in 2025 to USD 1.88 billion in 2033, growing at a CAGR of 5.50% during the forecast period (2025–2033).
Docetaxel is used in chemotherapy for treating breast, prostate, stomach, and non-small cell lung cancers. Increasing number of incidences of these cancers are further influencing the demand for docetaxel. As per the American Cancer Society, around 174,650 new cases of prostate cancer were diagnosed in the U.S. in 2019. Moreover, docetaxel-based chemotherapy treatment has improved the survival rate among men in castration-sensitive prostate cancers, is typically well-tolerated by patients.
According to the National Cancer Institute, 228,150 new cases of lung cancer are estimated to be registered in the U.S. by the end of 2019, which makes up for almost 12.9% of the population. Furthermore, increasing environmental pollution in the developed and developing regions such as North America, Europe, and the Asia Pacific which is influencing rate of cancer.
Demand for docetaxel is increasing in chemotherapy, as more and more manufactures are investing in the research & development for product innovation. In 2016, Eagle Pharmaceuticals, received an approval from FDA for Docetaxel injection, and non-alcohol formula for the treatment of cancer. To support the increasing prevalence of cancer, governments in various countries are heavily investing in the research & development, and are increasing the number of their clinical trial. For instance, in September 2017, Starpharma announced that its phase 1 trial for DEP docetaxel with low toxicity.
| Study Period | 2021-2033 | CAGR | 5.50% |
| Historical Period | 2021-2023 | Forecast Period | 2025-2033 |
| Base Year | 2024 | Base Year Market Size | USD 1.10 Billion |
| Forecast Year | 2033 | Forecast Year Market Size | USD 1.88 Billion |
| Largest Market | North America | Fastest Growing Market | Europe |
Geographically, the global docetaxel market share is bifurcated into North America, Europe, Asia Pacific (APAC), and, Middle East & Africa (MEA).
North America have a huge presence of multispecialty cancer hospitals, research center, and advanced chemotherapy treatment, which is further boosting the market growth in the region. Moreover, geriatric population are highly prone to suffer from cancer, and the region is housing a huge greyed population. As per the American Cancer Society Inc., around 140,690 new cases of cancer were diagnosed among the Americans aged 85 and older. Besides, various pharmaceutical manufacturers are working on developing new combination of docetaxel drugs for the better treatment of cancer, which is expected to drive the market growth. For instance, Genentech received an approval from the FDA for subcutaneous injection in certain HER2-positive breast cancers. In September 2019, Bristol-Myers Squibb Company, Opdivo CheckMate -548, combination formula of docetaxel are under phase III trial.
In Canada, in 2019, around 220,400 new cases of cancer were diagnosed, and the disease killed 82,100 people, Canadian Cancer Society. Moreover, lung, colorectal, breast, and prostate cancers are responsible for about half of all the deaths occurred in 2019.
Europe has a huge presence of leading manufacturers such as Accord Healthcare, and Sandoz for anti-cancer drugs, which is positively impacting the market growth. Moreover, increasing demand for cancer drugs in chemotherapy is further escalating the regional growth. In Germany, 345.9 per 100,000 men are suffering from kidney stone, which is further influencing the demand of kidney stone.
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
The market is segmented into breast cancer, prostate cancer, non-small cell lung cancer, ovarian cancer, and other.
The global Docetaxel market is carved by application into breast cancer, prostate cancer, non-small cell lung cancer (NSCLC), ovarian cancer, and others (like stomach and head & neck cancers). Though each plays a role, breast cancer is anticipated to lead the market. This dominance is due to the high prevalence of breast cancer worldwide, particularly among women. Additionally, docetaxel is an established and effective treatment for various stages of breast cancer and its use in combination therapy is increasing, contributing to market growth. While breast cancer leads the way, the docetaxel market for prostate cancer and NSCLC is expected to grow steadily due to increased diagnosis of these cancers.
The market is segmented into hospitals, specialty clinics, and oncology centers.
Hospital segment dominates the market, this dominance is fuelled by their comprehensive facilities. Hospitals, as opposed to specialist clinics or oncology centers, have the staff and facilities necessary to handle complex operations such as the intravenous injection of docetaxel. This includes the ability to monitor patients, specialized equipment for preparing drugs, and a larger pool of professionals to handle any consequences. In addition, hospitals serve a wider range of patients with a range of tumours that can be treated with docetaxel, allowing them to provide more therapy than in specialized facilities. Hospitals are likely to remain the main end users in the future due to their well-equipped environment and ability to treat the greater number of cancer patients who need this drug, although specialty clinics and oncology centers are actively participating.
